Form 4: Jasper Therapeutics Director Receives Automatic Stock Option Grant

Jasper Therapeutics, Inc. Director Thomas G. Wiggans was granted options to purchase 7,500 shares of common stock as part of the company's non-employee director compensation policy.

Summary

• Thomas G. Wiggans, a Director at Jasper Therapeutics, Inc. (JSPR), received an automatic grant of stock options.
• The grant was for the right to buy 7,500 shares of Voting Common Stock.
• The exercise price for these options is $6.77 per share.
• The grant date was July 3, 2025.
• The options become exercisable on July 3, 2026, and expire on July 3, 2035.
• This grant was made pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides for an automatic grant of 7,500 shares on the date of each annual meeting of stockholders.
• Following this transaction, Thomas G. Wiggans beneficially owns 7,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled equity grant to a director, which is generally viewed as a positive for aligning interests, but does not contain new material information that would significantly alter the company's outlook.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The transaction is part of a pre-established, transparent Non-Employee Director Compensation Policy, indicating consistent corporate governance practices.

Negatives

• No explicit negatives are identified in this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided in this filing, which reports a past transaction.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain qualified board members and align their incentives with shareholder value creation.

Comparison to Industry Standards

• The automatic grant of stock options to non-employee directors is a standard compensation practice, comparable to policies seen at many publicly traded companies, especially those in the biotechnology sector like Jasper Therapeutics.
• While specific grant sizes vary, a grant of 7,500 shares for a non-employee director is within the typical range for companies of similar market capitalization and stage of development.

Related Party Transactions

• The grant of stock options to Director Thomas G. Wiggans constitutes a related party transaction, as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of the shareholders, potentially leading to better long-term performance and increased shareholder value.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant